转移性结直肠癌抗血管生成靶向治疗的研究进展

近年来,由于各种新的化疗药物及分子靶向药物的使用,转移性结直肠癌(metastatic colorectal cancer,m CRC)的个体化治疗逐步取得了重要的成果。研究表明,抗血管生成靶向药物与化疗药物的联合使用作为转移性结直肠癌的一线治疗方案,可明显改善治疗效果,延长患者的生存时间。血管内皮生长因子(vascularendothelial growth factor,VEGF)是肿瘤血管生成过程中最主要的因子。贝伐单抗是通过基因工程技术得到的针对血管内皮生长因子-A(VEGF-A)的单克隆抗体,作为抗血管生成靶向药物用于转移性结直肠癌的临床治疗。本文对近年来转移性结直肠癌的抗血管生成靶向治疗,尤其是贝伐单抗治疗的相关研究进展进行综述并展望未来抗血管生成靶向治疗的发展前景。

Anti-angiogenesis Targeted Therapy for Metastatic Colorectal Cancer: Current Situation and Future Perspectives

In recent years, the treatment of metastatic colorectal cancer (mCRC) has made important progress by means of variable new chemotherapy and molecular targeted medicine. As first-line treatment for metastatic colorectal cancer, many researches have showed that the combination of anti-angiogenesis targeted agents and chemotherapy drugs can significantly improve the clinical effects and prolong the survival time of patients. Vascular endothelial growth factor (VEGF) is the one of the most important factors in the process of tumor angiogenesis. As the anti-angiogenesis targeted drug for the clinical treatment of metastatic colorectal cancer, bevacizumab is a monoclonal antibody for vascular endothelial growth factorA (VEGF-A) which is obtained by genetic engineering technique. The development of anti-angiogenesis targeted therapy for mCRC, particularly bevacizumab, will be reviewed in this article. And the prospect of future anti-angiogenesis targeted therapy will be discussed.